Tirzepatide: la rivoluzione contro l'obesità senza chirurgia
Lilly recently introduced tirzepatide in Italy, an innovative drug that represents a breakthrough in the treatment of obesity, overweight with related comorbidities, and type 2 diabetes. Approved by AIFA, tirzepatide is now available by prescription. Its unique effect lies in the activation of GLP-1 hormone receptors, thus ensuring significant weight loss and improved glycemic control. This treatment, particularly indicated for those with a body mass index (BMI) of over 30, or over 27 with comorbidities, offers impressive results: a weekly dosage of 5 mg can achieve a 16% weight loss, while higher dosages can exceed 21%. In addition to weight loss, tirzepatide provides tangible benefits such as lower blood pressure, improved lipid profile, and a reduction in chronic low-grade inflammation. These results are particularly relevant for those suffering from obesity-related conditions, such as diabetes and cardiovascular problems. The drug is administered via a weekly subcutaneous injection, a simple and well-tolerated modality, thanks in part to the familiarity of diabetologists with this type of treatment. Obesity is a complex, often recurrent disease involving multiple physical and psychological mechanisms. Effective treatment requires the integration of lifestyle changes, physical activity, and a healthy diet. Tirzepatide offers a revolutionary opportunity for those living with obesity, providing a previously lacking pharmacological solution. Interviews with: Prof. Massimiliano Caprio, Professor of Endocrinology at San Raffaele University, Rome; Prof. Caterina Conte, Director of the Obesity Center at IRCCS Multimedica, Sesto San Giovanni (MI). #Obesity #MetabolicHealth #Tirzepatide #WeightLoss #NewTherapies 🛎️ Don't forget to subscribe to our channel to stay up-to-date on the latest medical news and turn on notifications for upcoming videos! 🛎️ ************************ 🔥 Follow us! WebTV: https://PianetaSalute.TV Magazine: https://www.PianetaSalute.online Instagram: / pianetasalute2.0 Twitter: / pianetasalute Facebook: / pianetasalute WhatsApp: https://whatsapp.com/channel/0029VaDP... Telegram: https://t.me/pianetasalute Digital terrestrial: National Channel 221 Pianeta Salute TV (00:00) - Launch of Tirzepatide in Italy (00:36) - Mechanism of action and benefits of the drug (01:10) - Indications for use: BMI and comorbidities (01:40) - Clinical results: weight reduction and prevention of Diabetes (2:45) - Weekly Dosage and Medical Prescription (3:45) - New Perspectives on Obesity Management (4:47) - The Complexity of Obesity as a Chronic Disease (7:43) - Appropriate Use of Tirzepatide and Integrated Management
